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 Abstract
Background: Angiogenesis is of crucial importance for endometrial tumor growth and Vascular Endothelial Growth 
Factor (VEGF) is the key mediator of angiogenesis. 
Objective: The purpose of our study was to assess the prognostic value of VEGF and its receptors in relation to 
endometrioid endometrial carcinomas.
Material and methods: In this study, we conducted an immunohistochemical evaluation of VEGF and VEGFRs 
expression in 84 tissue samples obtained from endometrioid endometrial cancer patients undergoing curative 
surgical treatment. 
Results: Out of 84 cancers, strong positive expression of VEGF was seen in 35 (42%) tumors. The overall strong 
positive rates were 33% for VEGFR-1 and for 15% for VEGFR-2. There was a significant correlation between clinical 
stage and VEGF and VEGFR-1 overexpression (p=0.027 and p=0.004, respectively). Additionally, there was a 
significant correlation between histological grade and VEGF and VEGFR-1 overexpression (p<0.001  and p<0.001, 
respectively). The 5-year DFS of patients with VEGF and VEGFR-1 overexpression was significantly lower than that 
of those with a weakly positive or negative tumor (p<0.001). 
Conclusion: Immunohistochemical evaluation of VEGF and VEGFR-1 overexpression may be a useful marker for 
predicting 5-year DFS in endometrioid endometrial cancer. 
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Introduction
Angiogenesis	has	been	shown	to	be	a	critical	aspect	of	en-
dometrial	 cancer	 growth	 and	 metastasis	 [1].	 The	 induction	 of	
angiogenesis	by	a	 tumor	 is	a	controlled	process,	 influenced	by	
angiogenic	and	angiostatic	factors	which	involves	a	complex	in-
teraction	between	tumor	and	endothelial	cells.	Among	the	many	
reported	angiogenic	 factors,	vascular	endothelial	growth	 factor	
(VEGF)	 is	 the	most	powerful	 endothelial-cell-specific	mitogen	
that	plays	a	key	role	in	the	complicated	process	of	angiogenesis	
[2].	It	has	been	shown	to	be	significantly	upregulated	in	various	
human	malignant	tumors	and	to	be	associated	with	tumor	angio-
genesis	and	disease	outcome	[3,	4].
The	effects	of	VEGF	are	mediated	through	binding	to	two	
homologous	VEGF	receptors,	VEGFR-1	(Flt-1)	and	VEGFR-2	
(KDR),	which	are	expressed	on	vascular	endothelial	cells.	Like	
other	 growth	 factor	 transmembrane	 tyrosine	 kinase	 receptors,	
VEGF	receptors	undergo	ligand-induced	dimerization.	This	trig-
gers	signal	transduction	by	promoting	receptor	phosphorylation	
and	subsequent	recruitment	of	specific	downstream	signal	trans-
duction	mediators.	VEGF	binding	to	VEGF	receptor-2	elicits	an	
efficient	 endothelial	 cell	 response.	Although	VEGF	 receptor-1	
binds	VEGF	with	high	affinity,	it	is	believed	to	act	primarily	by	
modulating	the	availability	of	VEGF	for	binding	to	VEGF	recep-
tor-2	[5,	6].
Besides	 established	prognostic	 factors	 in	 endometrial	 can-
cer,	 such	as	histologic	grade,	 stage,	depth	of	myometrial	 inva-
sion,	 and	pelvic	 lymph	node	metastasis,	 angiogenesis	 has	 also	
been	associated	with	survival	[7,	8].
The	purpose	of	our	study	was	to	assess	the	prognostic	value	
of	VEGF	and	its	receptors	in	relation	to	endometrioid	endome-
trial	carcinomas.
Material and methods
Patients and tumor specimens
A	 total	 of	 84	patients	with	 endometrioid	 endometrial	 can-
cers	(aged	54–72	years;	mean	age	–	62.8	years),	who	underwent	
a	total	abdominal	hysterectomy	with	bilateral	salpingoophorec-
tomy	at	the	Department	of	Gynecology	of	the	District	Hospital	
in	Bialystok,	were	 included	 in	 the	 study.	All	 patients	 had	 pri-
mary	cancers	and	were	receiving	first	surgical	treatment.	Patients	
gave	 informed	written	 consent	 for	 the	 study.	All	 tumors	were	
staged	 according	 to	 the	 criteria	 of	 the	 International	Federation	
of	 Gynecology	 and	 Obstetrics	 (FIGO).	 The	 histological	 grade	
was	 classified	 according	 to	 the	 criteria	 of	 the	 World	 Health	
Organization.	The	protocol	had	been	previously	approved	by	the	
Bioethical	 Committee	 of	 the	Medical	 University	 of	 Bialystok	
(R-I-003/115/2006).	There	were	32	patients	with	stage	I,	40	with	
stage	II,	and	12		stage	III	endometrioid	cancer.	The	samples	were	
grouped	 by	 histological	 grade:	 44	 grade	 1,	 29	 grade	 2	 and	 11	
grade	3	cancers.		
Immunohistochemical staining for VEGF and VEGFRs
Four-µm	 sections	 were	 cut	 from	 formalin-fixed	 paraffin	
embedded	tissue	with	a	microtome	and	dried	overnight	at	37°C	
on	a	silanized-slide	 (DakoCytomation,	Carpinteria,	CA,	USA).	
Samples	 were	 deparaffinized	 in	 xylene	 at	 room	 temperature	
for	80	min.	and	washed	with	a	graded	ethanol	 /	water	mixture	
and	then	with	distilled	water	and	stained	for	VEGF,	VEGFR-1	
(Flt-1)	and	VEGFR-2	(KDR)	by	the	labeled	streptavidin	biotin	
method	 using	 the	 LSAB2	 Kit	 (DakoCytomation,	 Carpinteria,	
CA,	USA).
Rabbit	 primary	polyclonal	 antibodies	 to	VEGF	and	VEG-
FRs	were	 used	 at	 a	 1:100	 dilution	 (Santa	Cruz	Biotechnology	
Inc.,	Santa	Cruz,	CA,	USA).	All	primary	antibodies	were	incu-
bated	 for	12h	at	4°C	 in	a	moist	 chamber.	The	binding	 sites	of	
peroxidase	were	determined	using	3,39-diaminobenzidine	as	the	
substrate.	The	sections	were	then	counterstained	with	hematoxy-
lin	for	microscopic	examination.	A	positive	control	section	was	
included	 in	 each	 staining	 run.	Positive	 controls	 for	 reaction	 to	
the	anti-VEGF	antibody	were	represented	by	paraffin-embedded	
sections	from	ovarian	carcinomas,	and	those	for	the	three	recep-
tors	included	paraffin-embedded	sections	from	human	placenta.	
As	negative	controls,	preimmune	rabbit	serum	or	antibodies	ab-
sorbed	with	respective	antigens	were	used	instead	of	the	primary	
antibodies.	
Immunohistochemical	staining	was	evaluated	according	 to	
Volm	et	al.	scoring	method	[9].	Briefly,	a	score	was	established	
 Streszczenie
Wstęp: Angiogeneza ma istotne znaczenie we wzroście raka endometrium. Naczyniowo-śródbłonkowy czynnik 
wzrostu (VEGF) jest kluczowym mediatorem angiogenezy. 
Cel pracy: W pracy oceniono wartość prognostyczną VEGF i jego receptorów w endometrioidalnym raku 
endometrium. 
Materiał i metody: Przeprowadzono immunohistochemiczną ocenę ekspresji VEGF i VEGFR w 84 preparatach 
uzyskanych od chorych leczonych operacyjnie.
Wyniki: Wśród 84 raków intensywnie dodatnią ekspresję VEGF obserwowano w 35 (42%) przypadków. 
Intensywnie dodatnią ekspresję VEGFR-1 stwierdzono w 33% a VEGFR-2 w 15% przypadków. Wykazano istotny 
statystycznie związek pomiędzy stopniem zaawansowania klinicznego a nadekspresją VEGF i VEGFR-1 (p=0,027 
i p=0,004 ). Ponadto, stwierdzono znamienny statystycznie związek pomiędzy nadekspresją VEGF i VEGFR-1 
a zróżnicowaniem histologicznym (p<0,001 i p<0,001). Pięcioletni czas przeżycia wolny od choroby (DFS) 
pacjentek, u których wykazano nadekspresję VEGF i VEGFR-1 był statystycznie znamiennie krótszy niż tych, 
u których ekspresji nie wykazano lub była ona słaba (p<0,001).
Wnioski: Immunohistochemiczna ocena ekspresji VEGF i VEGFR-1 może być przydatna w prognozowaniu 
pięcioletniego czasu przeżycia wolnego od choroby w raku endometrioidalnym.   
 Key words: VEGF / VEGFR-1 / VEGFR-2 / rak endometrium / 
         / czas wolny od choroby / 
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corresponding	to	the	sum	of	the	percentage	of	positive	cells	(0	
-	0%	immunopositive	cells;	1	-	25%	positive	cells;	2	-	26–50%	
positive	cells;	and	3	-	50%	positive	cells)	and	staining	intensity	
(0	 -	negative;	1	 -	weak;	2	 -	moderate;	and	3	 -	high).	The	sum	
for	 the	 assigned	values	of	 the	positive	 cell	 percentage	 and	 the	
staining	intensity	was	less	than	6.	Scores	between	0	and	2	were	
regarded	as	negative,	scores	of	3	and	4	as	weakly	positive,	and	
scores	of	5	and	6	as	strongly	positive.	The	staining	scores	of	5	
and	6	were	considered	to	indicate	overexpression.
Statistical analysis
Statistical	analysis	was	performed	using	Statistica	software	
version	8.0	 (StatSoft,	 Inc.,	StatSoft	Polska	Sp.	z	o.o.,	Poland).	
Data	are	expressed	as	mean	±	SD.	Fisher’s	exact	test	was	used	
to	determine	significance	between	the	two	groups.	A	chi-square	
test	 was	 used	 to	 evaluate	 the	 relationship	 between	 categorical	
variables.	A	p-value	of	<	0.05	was	considered	as	statistically	sig-
nificant.	
Results
VEGF	immunoexpression	was	localized	in	the	cytoplasm	of	
endometrial	 carcinoma	 cells	with	more	 diffuse	 staining	within	
the	stroma	and	stromal	cells.	The	positive	staining	of	VEGFR-1	
and	VEGFR-2	was	localized	in	the	cytoplasm.	
The	VEGF	 overexpression	 group	 consisted	 of	 35	 patients	
(42%)	out	of	84	endometrioid	adenocarcinomas.	Prognosis	 for	
patients	 with	 VEGF	 tumor	 overexpression	 was	 significantly	
poorer	than	for	those	with	a	VEGF	weakly	positive	or	negative	
tumor.	31%	of	the	stage	I	endometrioid	endometrial	carcinoma	
samples	were	VEGF-strong	positive,	while	38%	and	83%	repre-
sented	stage	II	and	III,	respectively.	(Table	I).	
There	was	 a	 significant	 correlation	 between	 clinical	 stage	
and	VEGF	and	VEGFR-1	overexpression	(p=0.027	and	p=0.004,	
respectively).	Additionally,	 there	 was	 a	 significant	 correlation	
between	 histological	 grade	 and	VEGF	 and	VEGFR-1	 overex-
pression	(p<0.001		and	p<0.001,	respectively).	VEGFR-2	over-
expression	did	not	correlate	with	tumor	stage	or	grade	of	differ-
entiation.	(Table	I	and	II).
Out	 of	 all	 examined	 samples,	 VEGFR-1	 and	 VEGFR-2	
overexpression	were	33%	and	15%,	respectively.	Patients	with	
VEGFR-1	 overexpression	 had	 a	 significantly	 worse	 prognosis	
than	 those	with	VEGFR-1	weakly	 positive	 or	 negative	 tumor.	
(Table	III).	
The	5-year	DFS	of	patients	with	VEGF	and	VEGFR-1	over-
expression	was	significantly	lower	than	of	those	with	a	weakly	
positive	or	negative	tumor	(p<0.001).	On	the	other	hand,	 there	
was	no	apparent	statistical	significance	in	the	5-year	DFS	for	pa-
tients	with	VEGFR-2	overexpression.	(Table	III).	
Discussion
Cancer	 of	 the	 uterus	 is	 the	 seventh	most	 commonly	 diag-
nosed	cancer	that	occurs	in	women,	with	189,000	new	cases	and	
45,000	deaths	occurring	worldwide	each	year	[10].	In	Poland,	the	
age-adjusted	incidence	was	13.7/100,000	women	annually	[11].
Angiogenesis	is	crucial	for	normal	growth	and	develop	ment	
and	in	protective	responses,	such	as	wound	healing	and	inflam-
mation	[12].	However,	aberrant	angio	genesis	can	occur	in	a	vari-
ety	of	pathological	settings	including	growth	and	dissemination	
of	tumors	[13].	
VEGF	has	been	identified	as	an	important	regulator	of	tumor	
angiogenesis	 in	 the	endometrium,	but	 its	 role	as	a	predictor	of	
metastases	and	survival	 is	yet	 to	be	defined.	The	expression	of	
VEGF	is	4	to	10	times	higher	at	the	invading	tumor	front	than	in	
the	central	tumor	areas.	Indeed,	it	has	been	shown	that	overex-
pression	of	VEGF	and	its	receptors	are	related	to	poor	prognosis	
in	patients	with	endometrial	carcinomas	 [1].	 In	various	human	
cancers,	VEGF	expression	was	correlated	with	tumor	angiogen-
esis	and	prognosis	[14,	15,	16,	17].	
Table I. The relationship between VEGF and VEGFRs overexpression  
and tumor stage. 
Table II. The relationship between VEGF and VEGFRs overexpression  
and tumor histologic grade. 
Table III. The correlation of VEGF and VEGFRs immunoexpression with 5-year 
DFS. 
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Also,	 in	 our	 study,	VEGF	 strong	 positive	 tumors	 showed	
a	poorer	prognosis	than	VEGF	negative	tumors.	There	was	a	trend	
towards	an	association	between	the	strong	positive	expression	of	
VEGF	and	5-year	DFS.	These	 results	 suggest	 that	VEGF	may	
be	an	 important,	clinically	relevant,	 inducer	of	angiogenesis	 in	
endometrioid	endometrial	cancer.	
However,	in	our	study,	the	overexpression	of	VEGFR-2	did	
not	 correlate	 with	 VEGF	 expression.	 Our	 results	 suggest	 that	
tumor	 angiogenesis,	 through	 the	 regulation	 of	VEGF	 in	 endo-
metrioid	endometrial	cancer,	may	be	independent	of	VEGFR-2	
status.	In	our	study,	strong	positive	expression	of	VEGFR-1	was	
significantly	associated	with	poor	survival.	These	results	suggest	
that	 tumor	angiogenesis	may	be	a	useful	marker	for	predicting	
5-year	DFS	in	endometrioid	cancer	and,	furthermore,	that	VEGF	
and	VEGFR-1	overexpression	are	significant,	independent,	prog-
nostic	factors.
In	 conclusion,	VEGF	 seems	 to	be	 an	 important,	 clinically	
relevant	 inducer	 of	 angiogenesis,	 and	 tumor	 angiogenesis	 as-
sessed	 by	 the	 immunohistochemistry	 of	VEGF	 and	VEGFR-1	
may	be	a	useful	marker	for	predicting	5-year	DFS.
Praca zgłoszona na IV Międzynarodową Konferencję Naukowo-
Szkoleniową  pt.: „Zdrowie kobiety wyzwaniem dla współczesnej 
medycyny” w Poznaniu, w dniach 25-26 czerwca 2010 roku.
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